InVivoMAb Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14)(VMH02202)抗體
一、中文名稱：InVivoMAb Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14)(VMH02202)，抗小鼠PD1抗體/體內(nèi)中和抗體/活性抗體
二、產(chǎn)品描述
PD-1（程序性死亡受體1，Programmed Death 1），是一種在活化的T細(xì)胞、B細(xì)胞和巨噬細(xì)胞表面表達(dá)的免疫檢查點(diǎn)蛋白，主要通過與其配體PD-L1（程序性死亡配體1）和PD-L2結(jié)合，調(diào)節(jié)免疫反應(yīng)并防止過度的免疫應(yīng)答。PD-1及其配體的相互作用在維持外周耐受性和預(yù)防自身免疫性疾病方面起著關(guān)鍵作用。然而，在腫瘤微環(huán)境中，癌細(xì)胞常常高表達(dá)PD-L1，從而抑制T細(xì)胞活性，幫助逃避免疫系統(tǒng)的攻擊。近年來，針對(duì)PD-1/PD-L1通路的免疫檢查點(diǎn)抑制劑（如納武利尤單抗和帕博利珠單抗）已被廣泛應(yīng)用于多種癌癥治療，顯著提高了患者的生存率和生活質(zhì)量。這些藥物通過阻斷PD-1與PD-L1的結(jié)合，恢復(fù)T細(xì)胞對(duì)腫瘤細(xì)胞的殺傷能力。
三、產(chǎn)品詳情
名稱：InVivoMAb Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14) (VMH02202)
別名： Programmed cell death protein 1，CD279，hPD-1，PDCD1，Programmed Cell Death 1，Systemic Lupus Erythematosus Susceptibility 2，Protein PD-1，PD1，Programmed Cell Death 1 Protein，CD279 Antigen，HPD-L，HSLE1，SLEB2，PD-1，Programmed Cell Death 1 Receptor
貨號(hào)：VMH02202
種屬反應(yīng)性：Mouse
宿主：Mouse
同種型：IgG2a, kappa
克隆類型：Monoclonal
靶標(biāo)：Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
濃度：1 mg/ml
內(nèi)毒素水平：Please contact with the lab for this information.
純度：>95% as determined by SDS-PAGE.
純化方式：Protein A/G purified from cell culture supernatant.
Accession號(hào)：Q02242
克隆號(hào)：RMP1-14
應(yīng)用：Neutralization
狀態(tài)：Liquid
保存溶液：0.01M PBS, pH 7.4.
穩(wěn)定性和存儲(chǔ)：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions. PMID: 32324337
Utility of CD279/PD-1 immunohistochemistry in the evaluation of benign and neoplastic T-cell-rich bone marrow infiltrates. PMID: 24926091
PD-1 Blockers. PMID: 26317459
Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy. PMID: 30568661
Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma. PMID: 25011996
Artesunate upregulates the expression of CD39, CD279 and granzyme B in CD4(+) and CD8(+) T lymphocytes of patients with lung cancer. PMID: 35583064
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). PMID: 24359606
Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages. PMID: 34675601
Effects of Tussilago farfara L. Polysaccharides on the Expression of PD-1 (CD279) and PD-L1 (CD274) in Peripheral Blood and Tumor Tissue Lymphocytes in Mice with Lewis Lung Carcinoma. PMID: 32749562
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy. PMID: 37716115
Next generation of anti-immune checkpoints antibodies. PMID: 31903901
The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PMID: 29304116
CoViD-19 Immunopathology and Immunotherapy. PMID: 32308263
Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. PMID: 22094231
Peptide Blocking CTLA-4 and B7-1 Interaction. PMID: 33419027
PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma. PMID: 31620907
The association between polymorphisms in the PDCD1 gene and the risk of cancer: A PRISMA-compliant meta-analysis. PMID: 27749524
A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? PMID: 33808740
PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. PMID: 32937024
Epigenetic and Genetic Regulation of PDCD1 Gene in Cancer Immunology. PMID: 30178256
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. PMID: 35762356
Tumor Mutational Burden and Response Rate to PD-1 Inhibition. PMID: 29262275
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. PMID: 1396582
PD-L1/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior. PMID: 37348508
Identification of PDCD1 as a potential biomarker in acute rejection after kidney transplantation via comprehensive bioinformatic analysis. PMID: 36776400
CBX4 promotes antitumor immunity by suppressing Pdcd1 expression in T cells. PMID: 37691307
PD1 signal transduction pathways in T cells. PMID: 28881701
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. PMID: 35042524
Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies. PMID: 31417907
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. PMID: 34539412
Revisiting the PD-1 pathway. PMID: 32948597
PD1 Blockade in Cancer: Impact on Myeloid Cells. PMID: 32459997
Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. PMID: 35252014
Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy. PMID: 28367063
PD1 is transcriptionally regulated by LEF1 in mature T cells. PMID: 37523793
Emerging concepts in PD-1 checkpoint biology. PMID: 34006473
PD-L1/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior. PMID: 37348508
Quantification of the anti-murine PD-1 monoclonal antibody RMP1-14 in BALB/c mouse plasma by liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study. PMID: 31832706
Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells. PMID: 35820540
The Programmed Cell Death Ligand-1/Programmed Cell Death-1 Pathway Mediates Pregnancy-Induced Analgesia via Regulating Spinal Inflammatory Cytokines. PMID: 34524124
Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma. PMID: 37403798
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. PMID: 33447829
A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. PMID: 28288993
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. PMID: 31661001
詳情請(qǐng)咨詢Antibodysystem中國授權(quán)總代理-武漢佰樂博生物技術(shù)有限公司
網(wǎng)址：https://www.antibodysystem.com/product/14865.html
武漢佰樂博生物技術(shù)有限公司作為法國Antibodysystem品牌亞洲區(qū)授權(quán)總代理。提供近3萬種蛋白、抗體等核心生命科學(xué)試劑，旨在為生命科學(xué)科研工作者提供專業(yè)、全面、可靠的試劑產(chǎn)品。
試劑 | 耗材 | 定制 | 實(shí)驗(yàn)服務(wù) | 供應(yīng)鏈
免費(fèi)熱線：027-65279366 /18108604356